People · Operator
Named in public records as an officer, director or promoter · active 2012–2025 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Relmada Therapeutics, Inc. | — | Biotechnology | Series A | $36.1M | $29.9M | 2014 |
| Relmada Therapeutics, Inc. | — | Pharmaceuticals | Series B | $23.2M | $511.8M | 2012 |
| EnZeta Immunotherapies, Inc. | — | Biotechnology | Pre-Seed | $840K | $2.6M | 2025 |
Sergio Traversa at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Sergio Traversa on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Paul Kelly | 2 | 5 |
| Eliseo O. Salinas | 2 | 2 |
| Shreeram O. Agharkar | 2 | 2 |
| Sandesh O. Seth | 2 | 2 |
| Nabil M. Yazgi | 2 | 2 |
| Douglas O. Beck | 2 | 2 |
| Charles Casamento | 1 | 5 |
| Maged Shenouda | 1 | 3 |
| Chuck Ence | 1 | 1 |
| Najib Babul | 1 | 1 |
| Ottavio Vitolo | 1 | 1 |
| Sandesh Seth | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.